Third-Quarter 2020 Earnings

Baxter International Inc.

October 29, 2020

Forward-Looking Statements

This presentation includes forward-looking statements concerning Baxter's financial results, business development activities, capital structure, cost savings initiatives, R&D pipeline, including results of clinical trials and planned product launches, and outlook for full-year 2020. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand for and market acceptance of risks for new and existing products (including the impact of reduced hospital admission rates and elective surgery volumes); product development risks (including any delays in required regulatory approvals); product quality or patient safety concerns; continuity, availability and pricing of acceptable raw materials and component supply; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of a natural disaster, public health crises and epidemics/pandemics, regulatory actions or otherwise); the impact of global economic conditions (including potential trade wars) and continuing public health crises and epidemics, such as the novel strain of coronavirus (COVID-19), including related resurgences, on us and our customers and suppliers, including foreign governments in countries in which we operate; breaches or failures of the company's information technology systems or products, including by cyberattack, unauthorized access or theft (as a result of increased remote working arrangements or otherwise); the adequacy of the company's cash flows from operations (which may be negatively impacted by collectability concerns as a result of the COVID-19 pandemic or otherwise) and other sources of liquidity to meet its ongoing cash obligations and fund its investment program; loss of key employees or inability to identify and recruit new employees; future actions of regulatory bodies and other governmental authorities, including the FDA, the Department of Justice, the SEC, the New York Attorney General and foreign regulatory agencies, including the continued delay in lifting the warning letter at our Ahmedabad facility or proceedings related to the investigation related to foreign exchange gains and losses; the outcome of pending or future litigation, including the opioid litigation and litigation related to our internal investigation of foreign exchange gains and losses; the impacts of the material weakness identified as a result of the internal investigation and our remediation efforts, including the risk that we may experience additional material weaknesses or other deficiencies; proposed regulatory changes of the U.S. Department of Health and Human Services in kidney health policy and reimbursement, which may substantially change the U.S. end stage renal disease market and demand for our peritoneal dialysis products, necessitating significant multi-year capital expenditures, which are difficult to estimate in advance; failures with respect to compliance programs; accurate identification of and execution on business development and R&D opportunities and realization of anticipated benefits (including the acquisitions of Cheetah Medical and Seprafilm Adhesion Barrier from Sanofi); future actions of third parties, including payers; U.S. healthcare reform and other global austerity measures; pricing, reimbursement, taxation and rebate policies of government agencies and private payers; the impact of competitive products and pricing, including generic competition, drug reimportation and disruptive technologies; fluctuations in foreign exchange and interest rates; the ability to enforce owned or in-licensed patents or the prevention or restriction of the manufacture, sale or use of products or technology affected by patents of third parties; global, trade and tax policies; any change in laws concerning the taxation of income (including current or future tax reform), including income earned outside the United States and potential taxes associated with the Base Erosion and Anti-Abuse Tax; actions taken by tax authorities in connection with ongoing tax audits; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements unless otherwise required by the federal securities laws.

Use of Non-GAAP Financial Measures

To supplement Baxter's consolidated financial statements presented on a U.S. GAAP basis, the Company discloses certain non-GAAP financial measures. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States.

A reconciliation of the non-GAAP financial measures included in this document to the corresponding U.S. GAAP measures follows in the section titled Non-GAAP Reconciliations. In addition, an explanation of the ways in which Baxter management uses these supplemental non-GAAP measures to evaluate its business and the substantive reasons why Baxter management believes that these non-GAAP measures provide useful information to investors is included in the Company's most recent earnings release filed with the SEC on Form 8-K on October 29, 2020. This information should be considered in addition to, and not as substitutes for, information prepared in accordance with U.S. GAAP.

Baxter strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by the Company may differ from similar measures used by other companies, even when similar terms are used to identify such measures.

Non-GAAP financial measures used in this presentation include constant currency and operational sales growth, adjusted gross margin, adjusted operating margin, adjusted diluted EPS, free cash flow, adjusted selling, general, and administrative (SG&A) expense, and adjusted research and development (R&D) expense. A reconciliation to comparable U.S. GAAP measures can be found herein and is available at www.baxter.com.

Top Quartile Goals

- Patient safety and Quality
- Best place to work
- Growth through innovation
- Industry leading performance

Our Strategy

Strengthen our portfolio and extend our impact through transformative innovation that spans prevention to recovery

Table of Contents

Performance Highlights

Third-Quarter 2020

$2.97B
Sales

+4% Reported
+4% Constant Currency[1]
+3% Operational[2]

Key Metrics	GAAP	Adjusted[3]
Gross Margin	40.2%	42.6%
YOY Change	*(290 bps)*	*(310 bps)*
Operating Margin	15.8%	19.2%
YOY Change	*(180 bps)*	*(30 bps)*
Diluted EPS	$0.69	$0.83
YOY Change	*(3%)*	*+12%*

Year-To-Date 2020

$8.49B
Sales

+2% Reported
+3% Constant Currency[1]
+3% Operational[2]

Key Metrics	GAAP	Adjusted[3]
Gross Margin	40.0%	42.8%
YOY Change	*(160 bps)*	*(180 bps)*
Operating Margin	14.2%	18.1%
YOY Change	*(70 bps)*	*(10 bps)*
Diluted EPS	$1.81	$2.29
YOY Change	*(8%)*	*(2%)*

[1]Excludes the impact of foreign exchange. [2]Operational sales growth excludes the impact of foreign exchange and the Seprafilm acquisition. [3]Non-GAAP financial metrics referenced in this slide include constant currency sales growth and operational sales growth, adjusted gross margin, adjusted operating margin, and adjusted diluted EPS. A reconciliation to comparable U.S. GAAP measures can be found herein and is available at www.baxter.com.

Executing On Our Strategy

Recent Highlights

Demonstrating Underlying Portfolio Resilience In Dynamic Environment[1]

- Operational sales growth of 3% in Q3, driven by underlying business strength and ongoing demand for medically essential products
- Adjusted diluted EPS growth of 12% in Q3 reflects solid operational performance and the benefit of a lower tax rate

Investing In Growth Opportunities And Executing On A Robust Pipeline Of Launches[2]

- Granted U.S. Food and Drug Administration (FDA) De Novo authorization for Theranova and FDA approval of new higher protein formulations of Clinimix and Clinimix E for parenteral nutrition
- Received U.S. FDA Emergency Use Authorizations (EUAs) for Regiocit replacement solution, HF20 Set and ST Set for use in CRRT[3]
- Announced a distribution agreement with bioMérieux, for the NEPHROCLEAR™ CCL14 diagnostic test
- Supported a new investigator-initiated study demonstrating the role of indirect calorimetry (IC) in improving the accuracy of measuring COVID-19 patients' nutritional needs during their intensive care unit stay

Delivering Enhanced Value For Shareholders

- Announced quarterly dividend of $0.245 per share, reflecting strong financial position and commitment to driving value for investors
- Expect to recommence share repurchase activity in Q4; October 2020 Board approval increases available repurchase authorization to $2.4 billion of common stock

Creating A Best Place To Work And Demonstrating Leadership In Corporate Social Responsibility

- Ranked among the top 10% on the 2020 Diversity Best Practices Inclusion Index; ranked number 40 by *Forbes* and JUST Capital on the 2021 Just 100 list of America's "Most Just" companies; named to *Working Mother's* 100 Best Companies and Best Companies for Dads

Addressing Today's Unique Challenges While Continuing To Identify Opportunities To Drive Additional Value For All Stakeholders Over The Long-Term

Baxter

[1]Non-GAAP financial metrics referenced in this slide include operational sales growth and adjusted diluted EPS growth. A reconciliation to comparable U.S. GAAP measures can be found herein and is available at www.baxter.com. [2]See www.baxter.com for original press releases with additional product information. [3]Continuous Renal Replacement Therapy.

Key Financial Metrics

Third-Quarter 2020 Snapshot[1]

Global Reported Sales

Adjusted Operating Margin



Adjusted Diluted EPS

Baxter

[1]Non-GAAP financial metrics referenced in this slide include operational sales growth, adjusted operating margin, and adjusted diluted EPS. A reconciliation to comparable U.S. GAAP measures can be found herein and is available at www.baxter.com. [2]Q3 2020 operational sales growth excludes the impact of foreign exchange of approximately 0% and the Seprafilm acquisition impact of approximately 1%; U.S. GAAP sales growth for the period was approximately 4% compared to Q3 2019.

Key Financial Metrics

Year-To-Date 2020 Snapshot[1]



Baxter

[1]Non-GAAP financial metrics referenced in this slide include operational sales growth, adjusted operating margin, and adjusted diluted EPS. A reconciliation to comparable U.S. GAAP measures can be found herein and is available at www.baxter.com. [2]YTD 2020 operational sales growth excludes the impact of foreign exchange of approximately (1%) and the Seprafilm acquisition impact of approximately 1%; U.S. GAAP sales growth for the period was approximately 2% compared to YTD 2019.

Demonstrating Portfolio Resiliency Amid COVID-19

Third-Quarter 2020 Business Drivers[1,2]

Renal Care

$955M, +4% Constant Currency

Growth in both PD and HD businesses globally; PD sales benefitted from 6% patient growth in the U.S. and APAC region

Medication Delivery

$680M, (3%) Constant Currency

Strong execution of infusion pumps, led by Evo IQ placements internationally, offset by impact from lower hospital admissions and surgical procedures

Pharmaceuticals

$540M, +1% Constant Currency

Demand for international pharmacy compounding and one-time U.S. government purchase partially offset by reduced hospital utilization, U.S. TDS[3] competition and lower international demand for inhaled anesthetics

Clinical Nutrition

$237M, +5% Constant Currency

Strong performance driven by the benefit of recent new product launches, increased demand for Automated Nutrition Compounding business and competitor shortages in amino acids

Advanced Surgery

$236M, +9% Constant Currency

Growth driven by continued benefits from the Seprafilm acquisition, partially offset by the impact of declining surgical procedures

Acute Therapies

$177M, +35% Constant Currency

Continued heightened demand for continuous renal replacement therapy products in the midst of the pandemic

Baxter

[1]Sales and related figures represent Q3 2020; Other sales represent ~$0.1B. [2]Non-GAAP financial metrics referenced in this slide include constant currency sales growth. A reconciliation to comparable U.S. GAAP measures can be found herein and is available at www.baxter.com. [3]Transderm Scop.

Financial Results

Third-Quarter 2020 Earnings

October 29, 2020

Third-Quarter 2020 Sales By Global Business Unit[1]

$ In Millions	Q3 2020 Revenue			Total Growth		
	U.S.	International	Total	Reported	Constant	Operational
Renal Care	$216	$739	$955	+4%	+4%	+4%
Medication Delivery	$434	$246	$680	(3%)	(3%)	(3%)
Pharmaceuticals	$210	$330	$540	+2%	+1%	+1%
Clinical Nutrition	$90	$147	$237	+8%	+5%	+5%
Advanced Surgery	$139	$97	$236	+9%	+9%	(5%)
Acute Therapies	$72	$105	$177	+36%	+35%	+35%
Other	$83	$64	$147	+5%	+4%	+4%
Total Baxter	**$1,244**	**$1,728**	**$2,972**	**+4%**	**+4%**	**+3%**

[1]Non-GAAP financial metrics referenced in this slide include constant currency sales growth and operational sales growth. A reconciliation to comparable U.S. GAAP measures can be found herein and is available at www.baxter.com.

Year-To-Date 2020 Sales By Global Business Unit[1]

$ In Millions	YTD 2020 Revenue			Total Growth		
	U.S.	International	Total	Reported	Constant	Operational
Renal Care	$629	$2,115	$2,744	+2%	+5%	+5%
Medication Delivery	$1,296	$686	$1,982	(2%)	(1%)	(1%)
Pharmaceuticals	$653	$899	$1,552	(1%)	(1%)	(1%)
Clinical Nutrition	$250	$426	$676	+6%	+7%	+7%
Advanced Surgery	$370	$258	$628	(3%)	(2%)	(13%)
Acute Therapies	$204	$315	$519	+33%	+35%	+35%
Other	$186	$205	$391	+6%	+7%	+7%
Total Baxter	**$3,588**	**$4,904**	**$8,492**	**+2%**	**+3%**	**+3%**

Baxter

[1]Non-GAAP financial metrics referenced in this slide include constant currency sales growth and operational sales growth. A reconciliation to comparable U.S. GAAP measures can be found herein and is available at www.baxter.com.

Third-Quarter 2020 Sales By Operating Segment[1]

	Q3 2020 Revenue	Total Growth		
$ In Millions	Reported	Reported	Constant	Operational
Americas (North and South America)	$1,549	+1%	+2%	+1%
EMEA (Europe, Middle East and Africa)	$777	+6%	+3%	+3%
APAC (Asia Pacific)	$646	+10%	+7%	+5%
Total Baxter	**$2,972**	**+4%**	**+4%**	**+3%**

[1]Non-GAAP financial metrics referenced in this slide include constant currency sales growth and operational sales growth. A reconciliation to comparable U.S. GAAP measures can be found herein and is available at www.baxter.com.

Year-To-Date 2020 Sales By Operating Segment[1]

$ In Millions	YTD 2020 Revenue	Total Growth		
	Reported	Reported	Constant	Operational
Americas (North and South America)	$4,455	(0%)	+2%	+1%
EMEA (Europe, Middle East and Africa)	$2,262	+4%	+4%	+4%
APAC (Asia Pacific)	$1,775	+6%	+7%	+5%
Total Baxter	**$8,492**	**+2%**	**+3%**	**+3%**

Baxter

[1]Non-GAAP financial metrics referenced in this slide include constant currency sales growth and operational sales growth. A reconciliation to comparable U.S. GAAP measures can be found herein and is available at www.baxter.com.

Third-Quarter 2020 Adjusted Financial Results[1]

	Q3 2019	Q3 2020	Change
Adjusted Gross Margin	45.7%	42.6%	(310 bps)
Adjusted SG&A Expense (% of Sales)	21.5%	19.3%	(220 bps)
Adjusted R&D Expense (% of Sales)	4.7%	4.1%	(60 bps)
Adjusted Operating Margin	19.5%	19.2%	(30 bps)
Adjusted Diluted EPS	$0.74	$0.83	+12%

[1]Non-GAAP financial metrics referenced in this slide include adjusted gross margin, adjusted SG&A expense, adjusted R&D expense, adjusted operating margin, and adjusted diluted EPS. A reconciliation to comparable U.S. GAAP measures can be found herein and is available at www.baxter.com.

Year-To-Date 2020 Adjusted Financial Results[1]

	YTD 2019	YTD 2020	Change
Adjusted Gross Margin	44.6%	42.8%	(180 bps)
Adjusted SG&A Expense (% of Sales)	21.8%	20.5%	(130 bps)
Adjusted R&D Expense (% of Sales)	4.7%	4.3%	(40 bps)
Adjusted Operating Margin	18.2%	18.1%	(10 bps)
Adjusted Diluted EPS	$2.34	$2.29	(2%)

[1]Non-GAAP financial metrics referenced in this slide include adjusted gross margin, adjusted SG&A expense, adjusted R&D expense, adjusted operating margin, and adjusted diluted EPS. A reconciliation to comparable U.S. GAAP measures can be found herein and is available at www.baxter.com.

Maintaining Focus On Cash Flow Generation[1]

Operating Cash Flow[2]

Capital Expenditures



Free Cash Flow[3]

Baxter

[1]Non-GAAP financial metrics referenced in this slide include free cash flow. A reconciliation to comparable U.S. GAAP measures can be found herein and is available at www.baxter.com.
[2]From continuing operations. [3]Operating cash flow from continuing operations less capital expenditures.

Prioritizing Financial Flexibility While Driving Value For Shareholders Over The Long-Term

Reinvestment In Business
Meeting the needs of patients and providers globally while continuing to invest in long-term innovation and accelerated launch cadence

Dividend Issuance
Announced a quarterly dividend of $0.245 per share; continuing to target ~35% dividend payout ratio over time

Share Repurchase Program
We expect to recommence our share repurchase activity in the fourth quarter of 2020; recent Board approval increases available repurchase authorization to $2.4 billion of common stock as of October 29, 2020

Strategic Business Development
Focusing investments on strategic opportunities to augment current portfolio and position the company for future success

Enhanced Liquidity
~$4.4 billion of cash and cash equivalents as of September 30, 2020 with access to $2.0 billion and €200 million in revolving credit if necessary

Strong Balance Sheet Positioning Baxter For Sustained Durability In Dynamic Market Environment

Full-Year 2020 Outlook

Third-Quarter 2020 Earnings

October 29, 2020

Full-Year 2020 Guidance[1]

	Full-Year 2020 *Guidance*
Sales Growth *Reported*	**Low Single Digit**
Foreign Exchange	⬆ <100 bps
Sales Growth *Constant Currency*	**Low Single Digit**
Seprafilm Acquisition	⬇ ~80 bps
Sales Growth *Operational*	**Low Single Digit**
Adjusted Diluted EPS *Growth vs. Prior-Year Period*	**$3.02 - $3.05** *(9%) – (8%)*

[1]Non-GAAP financial metrics referenced in this slide include constant currency sales growth, operational sales growth, and adjusted diluted EPS. A reconciliation to comparable U.S. GAAP measures can be found herein and is available at www.baxter.com.

Non-GAAP Reconciliations

Third-Quarter 2020 Earnings

October 29, 2020

Non-GAAP Reconciliation as of October 29, 2020

Non-GAAP Reconciliations:

As part of its Q3 2020 earnings announcement on October 29, 2020, Baxter presented its financial results for the third quarter of 2020 and the related year-to-date period. Baxter also presented guidance for FY 2020. In these presentations, Baxter used non-GAAP financial measures of sales growth (on a constant currency and operational basis), adjusted gross margin, adjusted selling, general and administrative expense, adjusted research and development expense, adjusted operating income, adjusted operating margin, adjusted diluted earnings per share, and free cash flow. The reconciliations set forth below reconcile the non-GAAP measures set forth in this presentation for historical periods to the most directly comparable U.S. GAAP measures.

Description of Adjustments and Reconciliation of U.S. GAAP to Non-GAAP Measures

Three Months Ended September 30, 2020 and 2019

(unaudited)
(in millions, except per share and percentage data)

The company's U.S. GAAP results for the three months ended September 30, 2020 included special items which impacted the U.S. GAAP measures as follows:

	Gross Margin	Selling, General and Administrative Expenses	Research and Development Expenses	Other Operating Income, Net	Operating Income	Income Before Income Taxes	Income Tax Expense	Net income	Net Income Attributable to Baxter Stockholders	Diluted Earnings Per Share
Reported	$ 1,195	$ 601	$ 123	$ 1	$ 470	$ 415	$ 56	$ 359	$ 356	$0.69
Reported percent of net sales (or percent of income before income taxes for income tax expense)	40.2%	20.2%	4.1%	0.0%	15.8%	14.0%	13.5%	12.1%	12.0%	
Intangible asset amortization[1]	57	-	-	-	57	57	15	42	42	0.08
Business optimization items[2]	6	(25)	(1)	-	32	32	8	24	24	0.05
Acquisition and integration expenses[3]	-	-	-	(1)	1	1	-	1	1	0.00
European medical devices regulation[4]	8	-	-	-	8	8	2	6	6	0.01
Investigation and related costs[5]	-	(2)	-	-	2	2	-	2	2	0.00
Adjusted	$ 1,266	$ 574	$ 122	$ -	$ 570	$ 515	$ 81	$ 434	$ 431	$ 0.83
Adjusted percent of net sales (or adjusted percent of income before income taxes for income tax expense)	42.6%	19.3%	4.1%	0.0%	19.2%	17.3%	15.7%	14.6%	14.5%	

The company's U.S. GAAP results for the three months ended September 30, 2019 included special items which impacted the U.S. GAAP measures as follows:

	Gross Margin	Selling, General and Administrative Expenses	Research and Development Expenses	Other Operating Income, Net	Operating Income	Income Before Income Taxes	Income Tax Expense	Net income	Net Income Attributable to Baxter Stockholders	Diluted Earnings Per Share
Reported	$ 1,230	$ 627	$ 144	$ (44)	$ 503	$ 481	$ 106	$ 375	$ 369	$0.71
Reported percent of net sales (or percent of income before income taxes for income tax expense)	43.1%	22.0%	5.1%	(1.5%)	17.6%	16.9%	22.0%	13.2%	12.9%	
Intangible asset amortization[1]	48	-	-	-	48	48	15	33	33	0.06
Business optimization items[2]	10	(10)	(8)	-	28	28	8	20	20	0.04
Acquisition and integration expenses[3]	8	(3)	(2)	-	13	13	5	8	8	0.02
European medical devices regulation[4]	7	-	-	-	7	7	2	5	5	0.01
Insurance recoveries from a legacy product-related matter[6]	-	-	-	4	(4)	(4)	(1)	(3)	(3)	(0.01)
Hurricane Maria insurance recoveries[7]	-	-	-	40	(40)	(40)	(10)	(30)	(30)	(0.06)
U.S. tax reform[8]	-	-	-	-	-	-	16	(16)	(16)	(0.03)
Adjusted	$ 1,303	$ 614	$ 134	$ -	$ 555	$ 533	$ 141	$ 392	$ 386	$ 0.74
Adjusted percent of net sales (or adjusted percent of income before income taxes for income tax expense)	45.7%	21.5%	4.7%	0.0%	19.5%	18.7%	26.5%	13.7%	13.5%	

Description of Adjustments and Reconciliation of U.S. GAAP to Non-GAAP Measures

Three Months Ended September 30, 2020 and 2019

(unaudited)

1 The company's results in 2020 and 2019 included intangible asset amortization expense of $57 million ($42 million, or $0.08 per diluted share, on an after-tax basis) and $48 million ($33 million, or $0.06 per diluted share, on an after-tax basis), respectively.

2 The company's results in 2020 and 2019 included charges of $32 million ($24 million, or $0.05 per diluted share, on an after-tax basis) and $28 million ($20 million, or $0.04 per diluted share, on an after-tax basis), respectively, associated with its programs to optimize its organization and cost structure on a global basis.

3 The company's results in 2020 included $1 million ($1 million, or $0.00 per diluted share, on an after-tax basis) of acquisition and integration expenses related to the change in the estimated fair value of contingent consideration liabilities. The company's results in 2019 included $13 million ($8 million, or $0.02 per diluted share, on an after-tax basis) of acquisition and integration expenses. This included acquisition and integration expenses related to the company's acquisitions of Claris and the Recothrom and Preveleak products in prior periods and the purchase of in-process R&D assets.

4 The company's results in 2020 and 2019 included costs of $8 million ($6 million, or $0.01 per diluted share, on an after-tax basis) and $7 million ($5 million, or $0.01 per diluted share, on an after-tax basis) related to updating its quality systems and product labeling to comply with the new medical device reporting regulation and other requirements of the European Union's regulations for medical devices that are scheduled to become effective in 2021.

5 The company's results in 2020 included costs of $2 million ($2 million, or $0.00 per diluted share, on an after-tax basis) for investigation and related costs. This included costs related to the company's investigation of foreign exchange gains and losses associated with certain intra-company transactions and related legal matters.

6 The company's results in 2019 included a benefit of $4 million ($3 million, or $0.01 per diluted share, on an after-tax basis) related to its allocation of insurance proceeds received pursuant to a settlement and cost-sharing agreement for a legacy product-related matter.

7 The company's results in 2019 included a benefit of $40 million ($30 million, or $0.06 per diluted share, on an after-tax basis) related to insurance recoveries as a result of losses incurred due to Hurricane Maria.

8 The company's results in 2019 included updates to the estimated impact of U.S. federal tax reform previously made by the company of $16 million, or $0.03 per diluted share.

For more information on the company's use of non-GAAP financial measures in this presentation, please see the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this presentation.

Description of Adjustments and Reconciliation of U.S. GAAP to Non-GAAP Measures

Nine Months Ended September 30, 2020 and 2019

(unaudited)
(in millions, except per share and percentage data)

The company's U.S. GAAP results for the nine months ended September 30, 2020 included special items which impacted the U.S. GAAP measures as follows:

	Gross Margin	Selling, General and Administrative Expenses	Research and Development Expenses	Other Operating Income, Net	Operating Income	Income Before Income Taxes	Income Tax Expense	Net income	Net Income Attributable to Baxter Stockholders	Diluted Earnings Per Share
Reported	$ 3,396	$ 1,819	$ 386	$ (19)	$ 1,210	$ 1,082	$ 143	$ 939	$ 934	$1.81
Reported percent of net sales (or percent of income before income taxes for income tax expense)	40.0%	21.4%	4.5%	(0.2%)	14.2%	12.7%	13.2%	11.1%	11.0%	
Intangible asset amortization[1]	165	-	-	-	165	165	38	127	127	0.25
Business optimization items[2]	24	(53)	-	17	60	60	13	47	47	0.09
Acquisition and integration expenses[3]	11	(7)	(22)	2	38	38	8	30	30	0.06
European medical devices regulation[4]	22	-	-	-	22	22	6	16	16	0.03
Investigation and related costs[5]	3	(18)	(1)	-	22	22	4	18	18	0.03
Intangible asset impairment[6]	17	-	-	-	17	17	4	13	13	0.03
Adjusted	$ 3,638	$ 1,741	$ 363	$ -	$ 1,534	$ 1,406	$ 216	$ 1,190	$ 1,185	$2.29
Adjusted percent of net sales (or adjusted percent of income before income taxes for income tax expense)	42.8%	20.5%	4.3%	0.0%	18.1%	16.6%	15.4%	14.0%	14.0%	

The company's U.S. GAAP results for the nine months ended September 30, 2019 included special items which impacted the U.S. GAAP measures as follows:

	Gross Margin	Selling, General and Administrative Expenses	Research and Development Expenses	Other Operating Income, Net	Operating Income	Income Before Income Taxes	Income Tax Expense	Net income	Net Income Attributable to Baxter Stockholders	Diluted Earnings Per Share
Reported	$ 3,463	$ 1,869	$ 439	$ (81)	$ 1,236	$ 1,193	$ 163	$ 1,030	$ 1,024	$1.97
Reported percent of net sales (or percent of income before income taxes for income tax expense)	41.6%	22.5%	5.3%	(1.0%)	14.9%	14.3%	13.7%	12.4%	12.3%	
Intangible asset amortization[1]	136	-	-	-	136	136	34	102	102	0.20
Business optimization items[2]	39	(50)	(42)	-	131	131	29	102	102	0.20
Acquisition and integration expenses[3]	25	(8)	(8)	4	37	37	11	26	26	0.05
European medical devices regulation[4]	17	-	-	-	17	17	4	13	13	0.03
Intangible asset impairment[6]	31	-	-	-	31	31	7	24	24	0.05
Insurance recoveries from a legacy product-related matter[7]	-	-	-	37	(37)	(37)	(8)	(29)	(29)	(0.06)
Hurricane Maria insurance recoveries[8]	-	-	-	40	(40)	(40)	(10)	(30)	(30)	(0.06)
U.S. tax reform[9]	-	-	-	-	-	-	16	(16)	(16)	(0.03)
Adjusted	$ 3,711	$ 1,811	$ 389	$ -	$ 1,511	$ 1,468	$ 246	$ 1,222	$ 1,216	$2.34
Adjusted percent of net sales (or adjusted percent of income before income taxes for income tax expense)	44.6%	21.8%	4.7%	0.0%	18.2%	17.6%	16.8%	14.7%	14.6%	

Description of Adjustments and Reconciliation of U.S. GAAP to Non-GAAP Measures
Nine Months Ended September 30, 2020 and 2019
(unaudited)

1 The company's results in 2020 and 2019 included intangible asset amortization expense of $165 million ($127 million, or $0.25 per diluted share, on an after-tax basis) and $136 million ($102 million, or $0.20 per diluted share, on an after-tax basis), respectively.

2 The company's results in 2020 and 2019 included charges of $77 million ($64 million, or $0.12 per diluted share, on an after-tax basis) and $131 million ($102 million, or $0.20 per diluted share, on an after-tax basis), respectively, associated with its programs to optimize its organization and cost structure on a global basis. Additionally, we recorded a gain of $17 million ($17 million, or $0.03 per diluted share, on an after-tax basis) in 2020 for property we sold in conjunction with our business optimization initiatives.

3 The company's results in 2020 included $38 million ($30 million, or $0.06 per diluted share, on an after-tax basis) of acquisition and integration expenses. This included acquisition and integration expenses related to the company's acquisitions of Cheetah Medical and Seprafilm and the purchase of in-process R&D assets, partially offset by the change in the estimated fair value of contingent consideration liabilities. The company's results in 2019 included $37 million ($26 million, or $0.05 per diluted share, on an after-tax basis) of acquisition and integration expenses. This included acquisition and integration expenses related to the company's acquisitions of Claris and the Recothrom and Preveleak products in prior periods and the purchase of in-process R&D assets, partially offset by the change in the estimated fair value of contingent consideration liabilities.

4 The company's results in 2020 and 2019 included costs of $22 million ($16 million, or $0.03 per diluted share, on an after-tax basis) and $17 million ($13 million, or $0.03 per diluted share, on an after-tax basis) related to updating its quality systems and product labeling to comply with the new medical device reporting regulation and other requirements of the European Union's regulations for medical devices that are scheduled to become effective in 2021.

5 The company's results in 2020 included costs of $22 million ($18 million, or $0.03 per diluted share, on an after-tax basis) for investigation and related costs. This included costs related to the company's investigation of foreign exchange gains and losses associated with certain intra-company transactions and related legal matters. Additionally, the company recorded incremental stock compensation expense as it extended the terms of certain stock options that were scheduled to expire in the first quarter of 2020.

6 The company's results in 2020 and 2019 included charges of $17 million ($13 million, or $0.03 per diluted share, on an after-tax basis) and $31 million ($24 million, or $0.05 per diluted share, on an after-tax basis) for asset impairments related to developed-technology intangible assets.

7 The company's results in 2019 included a benefit of $37 million ($29 million, or $0.06 per diluted share, on an after-tax basis) related to its allocation of insurance proceeds received pursuant to a settlement and cost-sharing agreement for a legacy product-related matter.

8 The company's results in 2019 included a benefit of $40 million ($30 million, or $0.06 per diluted share, on an after-tax basis) related to insurance recoveries as a result of losses incurred due to Hurricane Maria.

9 The company's results in 2019 included updates to the estimated impact of U.S. federal tax reform previously made by the company of $16 million, or $0.03 per diluted share.

For more information on the company's use of non-GAAP financial measures in this presentation, please see the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this presentation.

Reconciliation of Non-GAAP Financial Measure
Operating Cash Flow to Free Cash Flow

(unaudited)
(in millions)

	Nine Months Ended September 30, 2020	Nine Months Ended September 30, 2019
Cash flows from operations - continuing operations	**$1,158**	**$1,281**
Capital expenditures	(472)	(505)
Free cash flow - continuing operations	**$686**	**$776**

Free cash flow is a non-GAAP measure. For more information on the company's use of non-GAAP financial measures in this presentation, please see the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this presentation.

Reconciliation of Non-GAAP Financial Measure
Change in Net Sales Growth As Reported to Operational Sales Growth
From The Three Months Ended September 30, 2019 to The Three Months Ended September 30, 2020
(unaudited)

Sales By Global Business Unit:

	Net Sales Growth As Reported	Seprafilm	FX	Operational Sales Growth*
Renal Care	4%	0%	0%	4%
Medication Delivery	(3%)	0%	0%	(3%)
Pharmaceuticals	2%	0%	(1%)	1%
Clinical Nutrition	8%	0%	(3%)	5%
Advanced Surgery	9%	(14%)	0%	(5%)
Acute Therapies	36%	0%	(1%)	35%
Other	5%	0%	(1%)	4%
Total Baxter	**4%**	**(1%)**	**0%**	**3%**
U.S.	2%	(1%)	0%	0%
International	6%	(1%)	(1%)	4%

*Totals may not add across due to rounding

Sales By Operating Segment:

	Net Sales Growth As Reported	Seprafilm	FX	Operational Sales Growth*
Americas	1%	(1%)	1%	1%
EMEA	6%	0%	(3%)	3%
APAC	10%	(2%)	(3%)	5%
Total Baxter	**4%**	**(1%)**	**0%**	**3%**

*Totals may add across due to rounding

Change in operational sales growth is a non-GAAP measure. For more information on the company's use of non-GAAP financial measures in this presentation, please see the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this presentation.

Reconciliation of Non-GAAP Financial Measure
Change in Net Sales Growth As Reported to Operational Sales Growth
From The Nine Months Ended September 30, 2019 to The Nine Months Ended September 30, 2020
(unaudited)

Sales By Global Business Unit:

	Net Sales Growth As Reported	Seprafilm	FX	Operational Sales Growth*
Renal Care	2%	0%	3%	5%
Medication Delivery	(2%)	0%	1%	(1%)
Pharmaceuticals	(1%)	0%	0%	(1%)
Clinical Nutrition	6%	0%	1%	7%
Advanced Surgery	(3%)	(10%)	1%	(13%)
Acute Therapies	33%	0%	2%	35%
Other	6%	0%	1%	7%
Total Baxter	**2%**	**(1%)**	**1%**	**3%**
U.S.	1%	(1%)	0%	0%
International	2%	(1%)	3%	4%

*Totals may not add across due to rounding

Sales By Operating Segment:

	Net Sales Growth As Reported	Seprafilm	FX	Operational Sales Growth*
Americas	(0%)	(1%)	2%	1%
EMEA	4%	0%	0%	4%
APAC	6%	(2%)	1%	5%
Total Baxter	**2%**	**(1%)**	**1%**	**3%**

*Totals may add across due to rounding

Change in operational sales growth is a non-GAAP measure. For more information on the company's use of non-GAAP financial measures in this presentation, please see the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this presentation.

Reconciliation of Non-GAAP Financial Measure
Projected Full Year 2020 U.S. GAAP Earnings Per Share to Projected Adjusted Earnings Per Share

(unaudited)

Earnings Per Share Guidance	FY 2020*
Earnings per Diluted Share – U.S. GAAP	**$2.41 - $2.44**
Estimated intangible asset amortization	$0.33
Estimated business optimization charges	$0.10
Estimated acquisition and integration expenses	$0.06
Estimated investigation and related costs	$0.04
Estimated European medical devices regulation	$0.05
Intangible asset impairment	$0.03
Earnings per Diluted Share - Adjusted	**$3.02 - $3.05**

*Totals may not foot due to rounding

The company's outlook for U.S. GAAP earnings per share only includes the impact of special items that are known or expected as of the date of this presentation. Accordingly, actual U.S. GAAP earnings per share for the full year of 2020 may differ significantly from those amounts. For example, the company's outlook does not reflect the potential impact of future business or asset acquisitions or dispositions, intangible asset impairments, restructuring actions, developments related to gain or loss contingencies, debt extinguishment gains or losses, or unusual or infrequently occurring items that may occur during the remainder of 2020.

Baxter

Third-Quarter 2020 Earnings

Baxter International Inc.

October 29, 2020